Obesity rates are fueling growth in the Praluent Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Praluent Market Expected To Change Between 2026 And 2030?

The expansion observed during the historical timeframe can be linked to the rising occurrence of hypercholesterolemia, the inherent inadequacies of treatments relying solely on statins, more frequent assessments for cardiovascular danger, the increasing availability of biological medications for heart conditions, and the growth in specialized heart care services.

The projected growth during the forecast period stems from an increased emphasis on aggressive lipid reduction strategies, a rising adoption in secondary prevention efforts, the expansion of value-based cardiovascular care services, growing financial support from payers for PCSK9 inhibitors, and heightened awareness regarding cardiovascular risk mitigation.

Major anticipated trends throughout the forecast period include the increasing utilization of PCSK9 inhibitors in lipid management, a growing prevalence of their adoption among high-risk cardiovascular patients, greater integration with statin combination therapies, the expansion of preventive cardiology initiatives, and an enhanced dedication to long-term LDL control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp

What Drivers Are Expected To Influence The Praluent Market During The Forecast Period?

The future expansion of the **Praluent market** is anticipated to be fueled by the growing incidence of obesity. This medical condition involves an unhealthy accumulation of body fat, generally identified by a Body Mass Index (BMI) of 30 or greater, which poses health risks. The increasing occurrence of obesity stems primarily from changes in global dietary patterns and food systems, including higher intake of ultra-processed items, less physical activity, and economic factors that favor less healthy food options. **Praluent** aids in managing obesity by lowering LDL cholesterol in individuals with dyslipidemia linked to obesity. As a PCSK9 inhibitor, it boosts the liver’s efficiency in clearing LDL cholesterol from the bloodstream, thereby enhancing cardiovascular well-being and mitigating obesity-related health issues. For example, in May 2024, a report from the Office for Health Improvement and Disparities, a UK-based government body overseeing public health, indicated that an estimated 64.0% of adults (18+) in England were overweight or obese between 2022 and 2023, with 26.2% specifically living with obesity (BMI ≥ 30 kg/m²). Consequently, the upward trend in obesity is set to propel the growth of the **Praluent market**. The growing embrace of personalized medicine is set to stimulate the expansion of the **Praluent market** in the future. Personalized medicine involves customizing treatments based on an individual’s unique biological traits to achieve superior patient outcomes. The increased acceptance of this approach is due to a growing inclination among medical professionals for treatments that precisely match genetic and biomarker profiles, leading to more accurate care. **Praluent** contributes to the rise of personalized medicine by offering a targeted PCSK9-inhibiting mechanism, which enables clinicians to adjust LDL-cholesterol reduction specifically to a patient’s cardiovascular risk profile. As an illustration, in February 2025, BioSpace, Inc., a U.S.-based life science news site, reported that the FDA cleared 16 new personalized treatments for patients with rare diseases in 2023, an increase from six approvals in 2022. Consequently, the rising adoption of personalized medicine is projected to propel the growth of the **Praluent market**.

How Is The Praluent Market Structured Across Different Segments?

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies

3) By End-User: Ambulatory Care, Home Care

Which Trends Are Shaping The Future Of The Praluent Market?

Key companies within the praluent market are prioritizing the development of innovative solutions, such as low-density lipoprotein cholesterol (LDL-C) lowering therapies, to fulfill the growing demand for advanced treatments that reduce cardiovascular risk. LDL-C–lowering therapies are specialized medical interventions designed to significantly decrease levels of “bad cholesterol,” providing more precise, targeted, and sustained lipid control compared to using traditional statins or lifestyle modifications alone. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained U.S. Food and Drug Administration (FDA) extended approval for Praluent (alirocumab) injection, an advanced LDL-C–lowering biologic therapy. This updated approval permits its use as an adjunct to diet and existing lipid-lowering treatments for pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). Praluent is a PCSK9 inhibitor monoclonal antibody engineered to boost LDL receptor availability, leading to a notable and lasting reduction in LDL-C. The therapy offers high efficacy, a favorable safety profile, and less frequent dosing compared to many conventional lipid-lowering options. By broadening access to children with genetic high cholesterol, the product assists in addressing early-onset cardiovascular risk and supports long-term heart health management.

Which Major Players Dominate The Praluent Market?

Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

Read the full praluent market report here:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

Which Region Is Forecast To Lead The Praluent Market In Terms Of Market Size?

North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Praluent Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20261&type=smp

Browse Through More Reports Similar to the Global Praluent Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795